title: [Effect of intravenous administration of SO4Mg in the acute phase of myocardial infarct].
abstract: Fifty four patients (p) with acute myocardial infarction (40M; 14F) were entered into a prospective study where they received either intravenous magnesium sulphate (group A-27 p) or placebo (group B-27 p). The incidence of arrhythmias necessitating treatment was greater in group B (37%) than in group A (15%). Mortality was 18.5% in group B and 3.7% in group A. These results suggest that magnesium sulphate administration reduces the incidence of arrhythmias and death after acute myocardial infarction.
authors.affiliation: Serviço de Cardiologia do Hospital de Vila Franca de Xira, Portugal.
authors.forename: D
authors.initials: D
authors.lastname: Pereira
authors.forename: T G
authors.initials: TG
authors.lastname: Pereira
authors.forename: C
authors.initials: C
authors.lastname: Rabaçal
authors.forename: E
authors.initials: E
authors.lastname: Carvalho
authors.forename: J
authors.initials: J
authors.lastname: Linder
authors.forename: J S
authors.initials: JS
authors.lastname: Afonso
authors.forename: J N
authors.initials: JN
authors.lastname: Pereira
authors.forename: M J
authors.initials: MJ
authors.lastname: Halpern
authors.forename: J S
authors.initials: JS
authors.lastname: Fernandes
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000517:prevention & control*; D004912:Erythrocytes / Q000032:analysis; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008274:Magnesium / Q000032:analysis / Q000097:blood; D008275:Magnesium Deficiency / Q000209:etiology / Q000517:prevention & control*; D008278:Magnesium Sulfate / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011446:Prospective Studies; D011897:Random Allocation
chemical_list: D008278:Magnesium Sulfate; D008274:Magnesium
vernacular_title: Efeito da administração de SO4Mg por via intra-venosa na fase aguda do enfarte do miocárdio.